Foghorn Therapeutics Inc.
FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activiā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.24
Price+4.80%
$0.24
1Y
Price
Market Cap
$296.316m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-183.9%
EBITDA Margin-194.4%
Net Profit Margin-231.3%
Free Cash Flow MarginRevenue
$24.518m
+8.5%
1y CAGR+17.4%
3y CAGR+352.5%
5y CAGREarnings
-$72.122m
+16.7%
1y CAGR+12.8%
3y CAGR+7.7%
5y CAGREPS
-$1.14
+27.9%
1y CAGR+23.7%
3y CAGR+19.2%
5y CAGRBook Value
-$89.658m
$204.962m
Assets$294.620m
Liabilities$22.529m
DebtDebt to Assets
11.0%
-0.3x
Debt to EBITDAFree Cash Flow
-$88.876m
+12.3%
1y CAGR-44.9%
3y CAGR+81.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company